AGYPHARMA, LLC

Biotech · Private

DHED (10β, 17β-dihydroxyestra-1,4-dien-3-one), a brain-selective estradiol prodrug therapeutic for prostate cancer ADT-induced vasomotor symptoms

Grants
$226K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A Novel Treatment of Vasomotor Symptoms in Prostate Cancer Patients$226,310
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3091ZETTA AI, LLC——
3092Technology Holding, LLC——
3093MADELEINE PHARMACEUTICALS, INC.——
3094AGYPHARMA, LLC——
3095TINY CARGO COMPANY, THE——
3096NEUROLUX, INC.——
3097NEW YORK/R&D/CTR/TRANSLATIONAL MED/THER——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.